For Innovators & Clinicians: While GLP-1 agonists represent one of the most significant therapeutic breakthroughs in decades, their commercial and clinical potential is capped by a critical, unmet challenge: long-term patient adherence. Studies show that up to 65% of patients discontinue their treatment within a year.
At CES 2025, we witnessed a wide array of AI-powered diagnostics and at-home health tech solutions. Discover how digital health innovators are addressing chronic diseases, overcoming commercialization challenges, and shaping the future of healthcare.
At the Consumer Electronics Show 2025, Orange Biomed showcased the OBM rapid A1c device, advancing healthcare with groundbreaking diabetes care innovation.
Discover Orange Biomed’s journey and innovations in diabetes technology after the Diabetes Technology Meeting 2024, focusing on health equity and solutions.
Explore innovations in A1C testing at the Diabetes Technology Meeting 2024. Learn about Orange Biomed’s OBM rapid A1c and its impact on equitable diabetes care.
Discover Orange Biomed’s revolutionary new A1c testing method, set to debut at ADA 2024. Get a preview before its public release and transform diabetes care.
ADA 2023 Recap: Discover Orange Biomed’s groundbreaking A1c testing method for improved diabetes management, diagnosis, and other key conference highlights.
Stay informed about our launch and get exclusive updates straight to your inbox. Fill out the form below, and we’ll make sure you’re among the first to know when OBM rapid A1c test hits the market.
"*" indicates required fields
